Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

von Hippel-Lindau Disease 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × PT2385 × Clear all
NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
4 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03216499 2022-05-09

PT2385

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
24 enrolled 11 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡